TY  - JOUR
AU  - von Hagens, Cornelia
AU  - Walter-Sack, Ingeborg
AU  - Goeckenjan, Maren
AU  - Osburg, Julia
AU  - Storch-Hagenlocher, Brigitte
AU  - Sertel, Serkan
AU  - Elsässer, Michael
AU  - Remppis, Bjoern Andrew
AU  - Edler, Lutz
AU  - Munzinger, Judith
AU  - Efferth, Thomas
AU  - Schneeweiss, Andreas
AU  - Strowitzki, Thomas
TI  - Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
JO  - Breast cancer research and treatment
VL  - 164
IS  - 2
SN  - 1573-7217
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V.
M1  - DKFZ-2017-01318
SP  - 359 - 369
PY  - 2017
AB  - The antimalarial drug artesunate (ART) is a promising candidate for cancer treatment as it displays anticancer effects in various models. While in short-term treatment of malaria, an excellent safety profile has been found for ART, the potential long-term treatment of cancer patients demands a phase I dose-finding clinical trial determining the daily ART dose which would be well tolerated as add-on therapy.Patients with metastatic breast cancer were to receive either 100 or 150 or 200 mg oral ART daily as add-on to their guideline-based oncological therapy for a study period of four weeks with frequent clinical and laboratory monitoring until 4-8 weeks thereafter. According to the statistical design, recruitment was scheduled in groups of three patients in order not to miss a more than 33
LB  - PUB:(DE-HGF)16
C6  - pmid:28439738
DO  - DOI:10.1007/s10549-017-4261-1
UR  - https://inrepo02.dkfz.de/record/124441
ER  -